肿瘤战争胜利？
1971年，当时美国总统Richard Nixon宣告对癌症开战！从那时开始，数以亿计的资金投入全球的癌症研究中，但是治愈肿瘤还有很长的路要走。本视频中，记者Lorna Stewart列了一个过去四十年的科研纪事表。她和诺奖得主Michael Bishop探讨肿瘤基因学，和Harald zur Hausen讨论疫苗。两个年轻科学家告诉她一些伟大的肿瘤研究的故事。
人类对战埃博拉：骇人战争中的制胜法宝
“埃博拉病毒威胁着我们的人性，”世界卫生组织的布鲁斯·艾尔沃德说。他用平静的手法带领我们重走埃博拉疫情爆发的过程 ﹣以及国际报警如何仅仅导致了问题以指数般增长。他分享四大关键性战略，以击败埃博拉病毒 ﹣ 以及它们是如何成功。这四大战略开始在利比理亚的洛法镇开始奏效，那是在爆发的中心，但已经几周内没有新的病例记录在案。布鲁斯·艾尔沃德强调，我们并未赢得对埃博拉病毒的斗争，但是如果我们做正确的事情，就能更乐观地看待我们的反击流行病的能力。
我战胜了癌症，但那并不代表什么
当被诊断出患了癌症时黛布拉·贾维斯已经在一家医院做了将近30年的牧师了。作为一名患者她学到了不少。在这个诙谐、大胆的演讲中，她解释了“癌症幸存者”的身份标识是如何让人们感到静止的。她希望我们在给自己成长和进步的空间的同时，定义自己最困难的历经，而不是被它们定义。
薛晴：子宫保卫战
女性子宫是用来做什么的？从受精到怀孕子宫经历了什么？人工流产真的能做到无痛人流吗？流产给子宫带来怎样的伤害？前置胎盘的危害有哪些？
薛主任的演讲，带来了令人震惊的数字，同时通俗易懂的介绍了女性子宫经历的那些伤害，呼吁女性们要更关爱自己的子宫健康。
本视频由Health Talk授权播出。
杨黄恬：干细胞与心肌修复：进展与挑战
心血管疾病是当今威胁人类健康最严重的疾病之一，其中由于心肌梗死引起心肌细胞丢失和瘢痕形成是导致心力衰竭的主要原因之一，其高发病率、高致残致死率已成为我国重大健康问题，并且呈现发病人群持续增加、年轻化等趋势，给我国家庭和社会带来沉重的负担。
虽然传统药物治疗、介入治疗和手术治疗等方法的应用改善了心肌梗死患者的预后，但无法修复坏死心肌细胞和逆转纤维疤痕， 只能延缓而不能阻止心衰的发生。因此寻找更有效的减轻心梗后细胞损伤与死亡、改善病变心肌血供、重建心肌的治疗手段是这一领域的前沿热点和探索目标。
近年的大量研究提示干细胞在治疗心梗后心肌病中的应用价值，但其临床应用仍有待开展一系列的基础和临床前的研究。在此将讨论近来在干细胞/祖细胞定向分化和动物与人心梗后心肌病治疗的研究进展和走向临床应用有待解决的问题。
我战胜了癌症，但那并不代表什么
当被诊断出患了癌症时黛布拉·贾维斯已经在一家医院做了将近30年的牧师了。作为一名患者她学到了不少。在这个诙谐、大胆的演讲中，她解释了“癌症幸存者”的身份标识是如何让人们感到静止的。她希望我们在给自己成长和进步的空间的同时，定义自己最困难的历经，而不是被它们定义。
HIV：免疫工程的大挑战 - David Baltimore P3
本视频由科普中国和生物医学大讲堂出品
David Baltimore (Caltech) Part 3: HIV: The Grand Challenge - Engineering Immunity
Lecture Overview:
In this set of lectures, I describe the threat facing the world from the human immunodeficiency virus (HIV) and a bold proposal on how we might meet the challenge of eliminating this disease by engineering the immune system.
In part 1, I provide a broad introduction to viruses, describing their basic properties and my own history of studying the replication of RNA viruses which led to the discovery of reverse transcriptase. I also illustrate the distinguishing features of equilibrium viruses (e.g. the common cold) that have adapted to co-exist with their host and non-equilibrium viruses (e.g. HIV) that have recently jumped from another species, are not adapted to the new host, and which can lead to disastrous outcomes (e.g. loss of immune function with potential lethality in the case of HIV).
In part 2, I describe the growing health problem that is facing the world with the spread of HIV and the limitations of current drug therapies and vaccine strategies. We need new ideas for tackling this problem. Here and in the next segment, I describe bold strategies of using gene therapy to conquer HIV, The approach that I describe in this segment involves gene therapy to produce short hairpin RNAs (siRNA) that target the destruction of a critical co-receptor of HIV, which the viruses that needs to infect cells. I discuss initial proof-of-principle experiments that suggest this approach might be feasible and the next steps needed to develop this idea into a real therapy.
In this last segment, I describe another gene therapy strategy for HIV in which we propose to develop antibody-like proteins that can be expressed by a patient's B cells and will target the HIV virus for destruction. To achieve this objective, hematopoietic (blood) stem cells must to be targeted with the gene, which will ultimately develop into B cells that express the therapeutic molecule. The ultimate goal is to produce a life-long supply of anti-HIV neutralizing antibodies. In this lecture, I describe the molecular methods underlying this strategy and a development path from proof-of-principle studies in mouse to safe trials in humans. This project receives funding from the Bill and Melinda Gates Foundation.
Speaker Bio:
After serving as President of the California Institute of Technology for nine years, in 2006 David Baltimore was appointed President Emeritus and the Robert Andrews Millikan Professor of Biology. Born in New York City, he received his B.A. in Chemistry from Swarthmore College in 1960 and a Ph.D. in 1964 from Rockefeller University, where he returned to serve as President from 1990-91 and faculty member until 1994.
For almost 30 years, Baltimore was a faculty member at Massachusetts Institute of Technology. While his early work was on poliovirus, in 1970 he identified the enzyme reverse transcriptase in tumor virus particles, thus providing strong evidence for a process of RNA to DNA conversion, the existence of which had been hypothesized some years earlier. Baltimore and Howard Temin (with Renato Dulbecco, for related research) shared the 1975 Nobel Prize in Physiology or Medicine for their discovery, which provided the key to understanding the life-cycle of HIV. In the following years, he has contributed widely to the understanding of cancer, AIDS and the molecular basis of the immune response. His present research focuses on control of inflammatory and immune responses as well as on the use of gene therapy methods to treat HIV and cancer in a program called "Engineering Immunity".
Baltimore played an important role in creating a consensus on national science policy regarding recombinant DNA research. He served as founding director of the Whitehead Institute for Biomedical Research at MIT from 1982 until 1990. He co-chaired the 1986 National Academy of Sciences committee on a National Strategy for AIDS and was appointed in 1996 to head the National Institutes of Health AIDS Vaccine Research Committee.
In addition to receiving the Nobel Prize, Baltimore's numerous honors include the 1999 National Medal of Science, election to the National Academy of Sciences in 1974, the Royal Society of London, and the French Academy of Sciences. For 2007/8, he is President of the AAAS. He has published more than 600 peer-reviewed articles.